| Original language | English |
|---|---|
| Pages (from-to) | 328-357 |
| Number of pages | 30 |
| Journal | Hepatology |
| Volume | 67 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2018 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases. / Chalasani, Naga; Younossi, Zobair; Lavine, Joel E.; Charlton, Michael; Cusi, Kenneth; Rinella, Mary; Harrison, Stephen A.; Brunt, Elizabeth M.; Sanyal, Arun J.
In: Hepatology, Vol. 67, No. 1, 01.2018, p. 328-357.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - The diagnosis and management of nonalcoholic fatty liver disease
T2 - Practice guidance from the American Association for the Study of Liver Diseases
AU - Chalasani, Naga
AU - Younossi, Zobair
AU - Lavine, Joel E.
AU - Charlton, Michael
AU - Cusi, Kenneth
AU - Rinella, Mary
AU - Harrison, Stephen A.
AU - Brunt, Elizabeth M.
AU - Sanyal, Arun J.
N1 - Funding Information: Abbreviations: AASLD, American Association for the Study of Liver Diseases; ACG, American College of Gastroenterology; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; AUROC, area under the receiver operating curve; BMI, body mass index; CI, confidence interval; CLD, chronic liver disease; CT, computed tomography; CVD, cardiovascular disease; ELF, Enhanced Liver Fibrosis; FDA, U.S. Food and Drug Administration; FIB-4, fibrosis-4 index; FLD, fatty liver disease; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDL, high-density lipoprotein; HF, hepatic fibrosis; HS, hepatic steatosis; ICD-10, International Classification of Diseases, Tenth Revision; IR, insulin resistance; LDL, low-density lipoprotein; LT, liver transplantation; METs, metabolic equivalents; MetS, MetS, metabolic syndrome; MR, magnetic resonance; MRE, MR elastography; MRI, magnetic resonance imaging; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic fatty liver disease; NASH CRN, NASH Clinical Research Network; NFS, NAFLD fibrosis score; NIAAA, National Institute on Alcohol Abuse and Alcoholism; OCA, obeticholic acid; PNPLA-3, patatin-like phospholipase domain-containing protein 3; PPAR, peroxisome proliferator-activated receptor gamma; RCT, randomized controlled trial; SAF, Steatosis Activity Fibrosis; SH, steatohepatitis; T2DM, type 2 diabetes mellitus; TE, transient elas-tography; TG, triglyceride; TONIC, treatment of nonalcoholic fatty liver disease in children; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; VCTE, vibration controlled transient elastography; WD, Wilson’s disease.
PY - 2018/1
Y1 - 2018/1
UR - http://www.scopus.com/inward/record.url?scp=85030176004&partnerID=8YFLogxK
U2 - 10.1002/hep.29367
DO - 10.1002/hep.29367
M3 - Article
C2 - 28714183
AN - SCOPUS:85030176004
VL - 67
SP - 328
EP - 357
JO - Hepatology
JF - Hepatology
SN - 0270-9139
IS - 1
ER -